A cohort study of cervical screening using partial HPV typing and cytology triage

Mark Schiffman, Noorie Hyun, Tina R. Raine-Bennett, Hormuzd Katki, Barbara Fetterman, Julia C. Gage, Li C. Cheung, Brian Befano, Nancy Poitras, Thomas Lorey, Philip E. Castle, Nicolas Wentzensen

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

HPV testing is more sensitive than cytology for cervical screening. However, to incorporate HPV tests into screening, risk-stratification (“triage”) of HPV-positive women is needed to avoid excessive colposcopy and overtreatment. We prospectively evaluated combinations of partial HPV typing (Onclarity, BD) and cytology triage, and explored whether management could be simplified, based on grouping combinations yielding similar 3-year or 18-month CIN3+ risks. We typed ∼9,000 archived specimens, taken at enrollment (2007–2011) into the NCI-Kaiser Permanente Northern California (KPNC) HPV Persistence and Progression (PaP) cohort. Stratified sampling, with reweighting in the statistical analysis, permitted risk estimation of HPV/cytology combinations for the 700,000+-woman KPNC screening population. Based on 3-year CIN3+ risks, Onclarity results could be combined into five groups (HPV16, else HPV18/45, else HPV31/33/58/52, else HPV51/35/39/68/56/66/68, else HPV negative); cytology results fell into three risk groups (“high-grade,” ASC-US/LSIL, NILM). For the resultant 15 HPV group-cytology combinations, 3-year CIN3+ risks ranged 1,000-fold from 60.6% to 0.06%. To guide management, we compared the risks to established “benchmark” risk/management thresholds in this same population (e.g., LSIL predicted 3-year CIN3+ risk of 5.8% in the screening population, providing the benchmark for colposcopic referral). By benchmarking to 3-year risk thresholds (supplemented by 18-month estimates), the widely varying risk strata could be condensed into four action bands (very high risk of CIN3+ mandating consideration of cone biopsy if colposcopy did not find precancer; moderate risk justifying colposcopy; low risk managed by intensified follow-up to permit HPV “clearance”; and very low risk permitting routine screening.) Overall, the results support primary HPV testing, with management of HPV-positive women using partial HPV typing and cytology.

Original languageEnglish (US)
Pages (from-to)2606-2615
Number of pages10
JournalInternational Journal of Cancer
Volume139
Issue number11
DOIs
StatePublished - Dec 1 2016

Fingerprint

Triage
Cell Biology
Cohort Studies
Benchmarking
Colposcopy
Risk Management
Population
Referral and Consultation

Keywords

  • cancer
  • cervix
  • cytology
  • HPV
  • screening

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Schiffman, M., Hyun, N., Raine-Bennett, T. R., Katki, H., Fetterman, B., Gage, J. C., ... Wentzensen, N. (2016). A cohort study of cervical screening using partial HPV typing and cytology triage. International Journal of Cancer, 139(11), 2606-2615. https://doi.org/10.1002/ijc.30375

A cohort study of cervical screening using partial HPV typing and cytology triage. / Schiffman, Mark; Hyun, Noorie; Raine-Bennett, Tina R.; Katki, Hormuzd; Fetterman, Barbara; Gage, Julia C.; Cheung, Li C.; Befano, Brian; Poitras, Nancy; Lorey, Thomas; Castle, Philip E.; Wentzensen, Nicolas.

In: International Journal of Cancer, Vol. 139, No. 11, 01.12.2016, p. 2606-2615.

Research output: Contribution to journalArticle

Schiffman, M, Hyun, N, Raine-Bennett, TR, Katki, H, Fetterman, B, Gage, JC, Cheung, LC, Befano, B, Poitras, N, Lorey, T, Castle, PE & Wentzensen, N 2016, 'A cohort study of cervical screening using partial HPV typing and cytology triage', International Journal of Cancer, vol. 139, no. 11, pp. 2606-2615. https://doi.org/10.1002/ijc.30375
Schiffman M, Hyun N, Raine-Bennett TR, Katki H, Fetterman B, Gage JC et al. A cohort study of cervical screening using partial HPV typing and cytology triage. International Journal of Cancer. 2016 Dec 1;139(11):2606-2615. https://doi.org/10.1002/ijc.30375
Schiffman, Mark ; Hyun, Noorie ; Raine-Bennett, Tina R. ; Katki, Hormuzd ; Fetterman, Barbara ; Gage, Julia C. ; Cheung, Li C. ; Befano, Brian ; Poitras, Nancy ; Lorey, Thomas ; Castle, Philip E. ; Wentzensen, Nicolas. / A cohort study of cervical screening using partial HPV typing and cytology triage. In: International Journal of Cancer. 2016 ; Vol. 139, No. 11. pp. 2606-2615.
@article{1916b0c403c241118d8db2b22df933d6,
title = "A cohort study of cervical screening using partial HPV typing and cytology triage",
abstract = "HPV testing is more sensitive than cytology for cervical screening. However, to incorporate HPV tests into screening, risk-stratification (“triage”) of HPV-positive women is needed to avoid excessive colposcopy and overtreatment. We prospectively evaluated combinations of partial HPV typing (Onclarity, BD) and cytology triage, and explored whether management could be simplified, based on grouping combinations yielding similar 3-year or 18-month CIN3+ risks. We typed ∼9,000 archived specimens, taken at enrollment (2007–2011) into the NCI-Kaiser Permanente Northern California (KPNC) HPV Persistence and Progression (PaP) cohort. Stratified sampling, with reweighting in the statistical analysis, permitted risk estimation of HPV/cytology combinations for the 700,000+-woman KPNC screening population. Based on 3-year CIN3+ risks, Onclarity results could be combined into five groups (HPV16, else HPV18/45, else HPV31/33/58/52, else HPV51/35/39/68/56/66/68, else HPV negative); cytology results fell into three risk groups (“high-grade,” ASC-US/LSIL, NILM). For the resultant 15 HPV group-cytology combinations, 3-year CIN3+ risks ranged 1,000-fold from 60.6{\%} to 0.06{\%}. To guide management, we compared the risks to established “benchmark” risk/management thresholds in this same population (e.g., LSIL predicted 3-year CIN3+ risk of 5.8{\%} in the screening population, providing the benchmark for colposcopic referral). By benchmarking to 3-year risk thresholds (supplemented by 18-month estimates), the widely varying risk strata could be condensed into four action bands (very high risk of CIN3+ mandating consideration of cone biopsy if colposcopy did not find precancer; moderate risk justifying colposcopy; low risk managed by intensified follow-up to permit HPV “clearance”; and very low risk permitting routine screening.) Overall, the results support primary HPV testing, with management of HPV-positive women using partial HPV typing and cytology.",
keywords = "cancer, cervix, cytology, HPV, screening",
author = "Mark Schiffman and Noorie Hyun and Raine-Bennett, {Tina R.} and Hormuzd Katki and Barbara Fetterman and Gage, {Julia C.} and Cheung, {Li C.} and Brian Befano and Nancy Poitras and Thomas Lorey and Castle, {Philip E.} and Nicolas Wentzensen",
year = "2016",
month = "12",
day = "1",
doi = "10.1002/ijc.30375",
language = "English (US)",
volume = "139",
pages = "2606--2615",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - A cohort study of cervical screening using partial HPV typing and cytology triage

AU - Schiffman, Mark

AU - Hyun, Noorie

AU - Raine-Bennett, Tina R.

AU - Katki, Hormuzd

AU - Fetterman, Barbara

AU - Gage, Julia C.

AU - Cheung, Li C.

AU - Befano, Brian

AU - Poitras, Nancy

AU - Lorey, Thomas

AU - Castle, Philip E.

AU - Wentzensen, Nicolas

PY - 2016/12/1

Y1 - 2016/12/1

N2 - HPV testing is more sensitive than cytology for cervical screening. However, to incorporate HPV tests into screening, risk-stratification (“triage”) of HPV-positive women is needed to avoid excessive colposcopy and overtreatment. We prospectively evaluated combinations of partial HPV typing (Onclarity, BD) and cytology triage, and explored whether management could be simplified, based on grouping combinations yielding similar 3-year or 18-month CIN3+ risks. We typed ∼9,000 archived specimens, taken at enrollment (2007–2011) into the NCI-Kaiser Permanente Northern California (KPNC) HPV Persistence and Progression (PaP) cohort. Stratified sampling, with reweighting in the statistical analysis, permitted risk estimation of HPV/cytology combinations for the 700,000+-woman KPNC screening population. Based on 3-year CIN3+ risks, Onclarity results could be combined into five groups (HPV16, else HPV18/45, else HPV31/33/58/52, else HPV51/35/39/68/56/66/68, else HPV negative); cytology results fell into three risk groups (“high-grade,” ASC-US/LSIL, NILM). For the resultant 15 HPV group-cytology combinations, 3-year CIN3+ risks ranged 1,000-fold from 60.6% to 0.06%. To guide management, we compared the risks to established “benchmark” risk/management thresholds in this same population (e.g., LSIL predicted 3-year CIN3+ risk of 5.8% in the screening population, providing the benchmark for colposcopic referral). By benchmarking to 3-year risk thresholds (supplemented by 18-month estimates), the widely varying risk strata could be condensed into four action bands (very high risk of CIN3+ mandating consideration of cone biopsy if colposcopy did not find precancer; moderate risk justifying colposcopy; low risk managed by intensified follow-up to permit HPV “clearance”; and very low risk permitting routine screening.) Overall, the results support primary HPV testing, with management of HPV-positive women using partial HPV typing and cytology.

AB - HPV testing is more sensitive than cytology for cervical screening. However, to incorporate HPV tests into screening, risk-stratification (“triage”) of HPV-positive women is needed to avoid excessive colposcopy and overtreatment. We prospectively evaluated combinations of partial HPV typing (Onclarity, BD) and cytology triage, and explored whether management could be simplified, based on grouping combinations yielding similar 3-year or 18-month CIN3+ risks. We typed ∼9,000 archived specimens, taken at enrollment (2007–2011) into the NCI-Kaiser Permanente Northern California (KPNC) HPV Persistence and Progression (PaP) cohort. Stratified sampling, with reweighting in the statistical analysis, permitted risk estimation of HPV/cytology combinations for the 700,000+-woman KPNC screening population. Based on 3-year CIN3+ risks, Onclarity results could be combined into five groups (HPV16, else HPV18/45, else HPV31/33/58/52, else HPV51/35/39/68/56/66/68, else HPV negative); cytology results fell into three risk groups (“high-grade,” ASC-US/LSIL, NILM). For the resultant 15 HPV group-cytology combinations, 3-year CIN3+ risks ranged 1,000-fold from 60.6% to 0.06%. To guide management, we compared the risks to established “benchmark” risk/management thresholds in this same population (e.g., LSIL predicted 3-year CIN3+ risk of 5.8% in the screening population, providing the benchmark for colposcopic referral). By benchmarking to 3-year risk thresholds (supplemented by 18-month estimates), the widely varying risk strata could be condensed into four action bands (very high risk of CIN3+ mandating consideration of cone biopsy if colposcopy did not find precancer; moderate risk justifying colposcopy; low risk managed by intensified follow-up to permit HPV “clearance”; and very low risk permitting routine screening.) Overall, the results support primary HPV testing, with management of HPV-positive women using partial HPV typing and cytology.

KW - cancer

KW - cervix

KW - cytology

KW - HPV

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=84988038853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988038853&partnerID=8YFLogxK

U2 - 10.1002/ijc.30375

DO - 10.1002/ijc.30375

M3 - Article

C2 - 27509172

AN - SCOPUS:84988038853

VL - 139

SP - 2606

EP - 2615

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 11

ER -